Leidos was awarded a pharma deal with prime contract by the U.S. Defense Threat Reduction Agency to conduct research and development to combat weapons of mass destruction.
The multiple-award indefinite delivery/indefinite quantity contract has a five-year base period of performance, a five year option, and a total value of approximately $4 billion for all awardees, if all options are exercised.
The contract was awarded under the Combating Weapons of Mass Destruction Research and Technology Development ID/IQ contract.
In October 2012, PositiveID entered into a Teaming Agreement with Leidos, which paired Leidos' system engineering and integration capabilities with PositiveID's bio-threat detection technologies.
PositiveID will offer both its Firefly Dx handheld diagnostic system ("Firefly") as well as its M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector as part of the Teaming Agreement.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Practical Guide to Finding Partners
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity